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Abstract
Glucocorticoids are steroid hormones that play a key role in metabolic adaptations during stress, 
such as fasting and starvation, in order to maintain plasma glucose levels. Excess and chronic 
glucocorticoid exposure, however, causes metabolic syndrome including insulin resistance, 
dyslipidemia, and hyperglycemia. Studies in animal models of metabolic disorders frequently 
demonstrate that suppressing glucocorticoid signaling improves insulin sensitivity and metabolic 
profiles. Glucocorticoids convey their signals through an intracellular glucocorticoid receptor 
(GR), which is a transcriptional regulator. The adipocyte is one cell type that contributes to whole 
body metabolic homeostasis under the influence of GR. Glucocorticoids’ functions on adipose 
tissues are complex. Depending on various physiological or pathophysiological states as well as 
distinct fat depots, glucocorticoids can either increase or decrease lipid storage in adipose tissues. 
In rodents, glucocorticoids have been shown to reduce the thermogenic activity of brown 
adipocytes. However, in human acute glucocorticoid exposure, glucocorticoids act to promote 
thermogenesis. In this article, we will review the recent studies on the mechanisms underlying the 
complex metabolic functions of GR in adipocytes. These include studies of the metabolic 
outcomes of adipocyte specific GR knockout mice and identification of novel GR primary target 
genes that mediate glucocorticoid action in adipocytes.
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1. Introduction
Glucocorticoids are steroid hormones that convey their signals through the intracellular 
glucocorticoid receptor (GR), which is a transcriptional regulator. Before binding to 
hormones or ligands, the majority of GR is localized in the cytosol and associates with the 
heat shock protein 90 (hsp90)-containing chaperone complex [1–4]. Upon binding to 
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hormones or ligands, the heterocomplex of GR-hsp90-containing chaperone complex can 
passage through the nuclear pore [1–4]. In the nucleoplasmic region, GR is dissociated from 
hsp90-containing chaperone complex and associates with genomic glucocorticoid response 
elements (GREs) to regulate the transcriptional rate of nearby genes. GR usually binds to 
GREs as a homodimer, though it could also modulate the transcription as a monomer 
through binding to the DNA [5] or interaction with other transcription factors [6]. 
Glucocorticoids play critical roles in the regulation of metabolic homeostasis. Upon stress, 
such as fasting and starvation, glucocorticoids exert their metabolic functions through 
multiple cell types to maintain plasma glucose levels, which is the major energy source for 
brain. Excess and/or chronic glucocorticoid exposure, however, causes metabolic disorders 
that include insulin resistance, hyperglycemia, dyslipidemia, and central obesity. 
Glucocorticoid excess does not need to be systemic to result in metabolic syndrome. In fact, 
patients with metabolic syndrome do not have elevated glucocorticoid levels but are thought 
to have elevated local levels of glucocorticoids in adipose tissue. This is possible due to local 
activation of glucocorticoids in adipose tissue by the enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), which encodes an enzyme that converts the inactive 
glucocorticoid cortisone to active the glucocorticoid cortisol or corticosterone [7, 8]. 
Interestingly, transgenic expression of 11β-HSD1 limited to adipose tissue, results in mice 
with metabolic syndrome while fed a chow diet [9]. In contrast, overexpression of 11β-
HSD2 (which inactivates glucocorticoids) in adipose tissue protects mice from metabolic 
complications of diet induced obesity [10]. Inhibitors of 11β-HSD1, have been in clinical 
trials for treating metabolic syndrome [7, 8, 11]. There are some adverse effects reported for 
11β-HSD1 inhibitors which include the compensatory increase of hypothalamus-pituitary-
adrenal (HPA) axis and an elevated androgen production [11, 12]. It is important to note that 
reducing glucocorticoid signaling in animal models of metabolic disorders usually improves 
their metabolic profiles and insulin sensitivity [13–15]. However, not surprisingly, reducing 
glucocorticoid signaling universally would result in undesired adverse effects.
Adipose tissue plays a key role in whole body metabolic homeostasis. Glucocorticoids affect 
multiple aspects of adipocyte biology. First, glucocorticoids are included in almost all 
differentiation media for adipogenesis in vitro. However, the exact role of glucocorticoids 
and GR in adipose tissue development in vivo has not been established. Second, 
glucocorticoids exert complex effects on lipid metabolism in adipose tissues. Upon fasting, 
glucocorticoids increase lipolysis in white adipose tissues, generating glycerol and fatty 
acids. The former is the precursor for hepatic gluconeogenesis whereas the latter is an 
energy source during fasting [16, 17]. However, in pathological states, glucocorticoid effects 
on lipid metabolism in adipose tissue are more complicated. Patients with Cushing’s 
syndrome, which is characterized by chronically elevated circulating cortisol levels, develop 
central obesity, but subcutaneous white adipose tissue is reduced, resulting in a 
lipodystrophy [18, 19]. The molecular basis of these fat depot specific effects of 
glucocorticoids is unclear. One possibility is depot-specific balance between lipogenic and 
lipolytic gene expression, which has been investigated in human visceral and subcutaneous 
adipose derived stem cells [20] as well as in adipose tissue harvested from obese individuals 
[21]. In fact, in rodents, chronic glucocorticoid exposure augments adiposity but is usually 
not restricted to visceral fat depots [22]. Third, glucocorticoids suppress insulin-stimulated 
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glucose uptake in adipocytes, which might contribute to the modulation of whole body 
glucose homeostasis and insulin sensitivity [23–25]. The mechanism underlying 
glucocorticoid-induced insulin resistance in adipocytes is not entirely clear. Notably, certain 
studies find that glucocorticoids enhance, rather than suppress, insulin actions in human 
primary adipocytes [26, 27]. Finally, glucocorticoids have been shown to repress the 
thermogenic activity of brown and beige adipocytes in rodents [28–31]. However, recent 
studies show that acute glucocorticoid exposure enhances the thermogenic activity of human 
brown adipose tissue [32]. The reason for such species-specific effects is unknown. Studies 
over the last several years have made significant contributions to our understanding of 
glucocorticoid functions in various aspects of adipocyte biology. We will review and discuss 
these new developments below.
2. The Role of Glucocorticoids and GR in Adipogenesis in vivo
Glucocorticoids are included in most differentiation protocols that are used to induce 
adipogenesis in vitro. Glucocorticoids have been shown to promote preadipocytes (3T3-L1 
and 10T1/2 cells) to an intermediate priming state before committing them to differentiation 
[33]. GR has been shown to act with other adipogenic transcription factors, such as C/EBPβ, 
to activate the transcription of PPARγ2, a master regulator of adipogenesis [34]. 
Transcriptional coregulators of GR [35] and some GR primary target genes are found to be 
required for adipocyte differentiation in vitro [36–38]. However, the exact role of GR in 
adipose tissue development had not been explored until two recent publications. GRflox/flox 
mice were crossed with mice expressing Cre recombinase under the control of Myf5 
promoter to delete the GR gene in brown adipocyte precursor cells [39]. There was no 
apparent difference in brown adipose tissue development between these mice and wild type 
mice. This suggests that GR is not required for brown adipose tissue development in vivo. 
Preadipocytes isolated from brown adipose tissue of brown fat specific GR knockout mice 
showed immature adipocytes at day seven of differentiation compared to those differentiated 
from preadipocytes of wild type mice. However, the number of mature adipocytes were 
comparable at day 14 and day 21 of differentiation [39]. Similar results were observed in 
preadipocytes isolated from inguinal white adipose tissue of GRflox/flox mice that were 
infected with adenoviruss expressing GFP or Cre recombinase [39]. These results 
demonstrate that GR is dispensable but can accelerate both white and brown adipocyte 
differentiation.
In another study, several approaches were used to test the role of GR and endogenous 
glucocorticoids in adipose tissue development. First, mouse embryonic fibroblasts (MEFs) 
isolated from GR knockout mice (by crossing GRflox/flox with actin−Cre mice) and wild type 
mice were both capable of forming de novo fat pads in mice [40]. However, GR-null fat pads 
and their associated adipocyte areas were smaller than those in controls [40]. Second, 
eliminating circulating corticosterone by adrenalectomy does not block the formation of de 
novo fat pads in mice, though the fat pads formed in adrenalectomized mice were smaller 
than those in control mice [40]. Moreover, using adipocyte-specific luciferase reporter, 
mouse adipocytes were identified in day 18 mouse embryos in both WT and GR-null mice 
[40]. Positive perilipin staining was also identified in day 18 embryos of WT and GR-null 
mice, which confirms the presence of early white inguinal and brown adipocytes [40]. 
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Overall, these in vivo studies indicate that while GR and glucocorticoids can promote 
adipocyte differentiation, they are not required for the development of brown and white 
adipose tissues.
3. Regulation of Lipid Metabolism by GR in White Adipocytes
As discussed above, patients with Cushing’s syndrome have increased visceral fat depots but 
decreased subcutaneous fat depots. This suggests that glucocorticoids can modulate both 
lipogenesis and lipolysis in white adipose tissue. Exogenous glucocorticoid treatment has 
been shown to stimulate both triglyceride synthesis and lipolysis in white adipose tissue 
[41]. Similarly, using stable isotope labeling techniques, it was found that de novo 
lipogenesis, triglyceride synthesis and lipolysis were all concurrently stimulated in white 
adipose tissues of corticotropin-releasing hormone overexpressing mice [22]. Thus, it is 
possible that other environmental factors in distinct fat depots affect the ability of 
glucocorticoids to modulate either lipogenesis and/or lipolysis. The change in the ratio of the 
rate of lipogenesis vs. lipolysis will result in alteration of adiposity. This notion, however, 
has not been examined.
Various reports have shown that glucocorticoid treatment on differentiated adipocytes 
enhances lipolysis [42, 43]. This response, however, requires a much longer treatment time 
than that of catecholamine. This is consistent with the fact that glucocorticoids mainly 
modulate gene expression levels, which need to be translated to proteins to affect cellular 
physiology. Glucocorticoids stimulate lipolysis in adipocytes through multiple mechanisms. 
It has been shown that glucocorticoid treatment decreases the expression of cyclic-
nucleotide phosphodiesterase 3B (Pde3b) in adipocytes, which results in elevated cAMP 
levels in adipocytes that potentiate lipolysis by phosphorylating hormone sensitive lipase 
(Hsl, a.k.a Lipe) and perilipin 1 (Figure 1) [42]. Notably, there is no GR binding site 
identified in or nearby the Pde3b gene locus. Thus, Pde3b may not be a primary target gene 
of GR. In contrast, glucocorticoids have been shown to activate the expression of genes 
encoding enzymes in the lipolytic pathway, such as hormone sensitive lipase (Lipe) [41], 
adipocyte triglyceride lipase (Atgl, a.k.a Pnpla2) [44] and monoglyceride lipase (Mgll) 
(Figure 1) [41]. All these three genes are potential GR primary target genes, as they contain 
GR binding regions in their genome. It has been shown that Atgl [45, 46] and Lipe [46] 
expression is significantly decreased in adipocyte specific GR knock out mice. However, the 
activity of these enzymes was not monitored. Therefore, the exact contribution of the 
induction of these lipolytic genes in glucocorticoid-promoted lipolysis in vivo is unclear. 
Notably, several GR primary target genes have been shown to be involved in glucocorticoid-
induced adipose tissue lipolysis in vivo. Angiopoietin-like 4 (Angptl4) is a GR primary 
target gene in hepatocytes and adipocytes that encodes a secreted protein [47]. The ability of 
exogenous glucocorticoids to promote adipose tissue lipolysis is reduced in Angptl4 null 
mice (Angptl4−/−) [47]. Glucocorticoid treatment elevates the levels of Hsl and perilipin 1 
phosphorylation in white adipose tissue of wild type mice but these effects are attenuated in 
Angptl4−/− mice [47]. Purified human ANGPTL4 protein is able to directly induce cAMP 
levels in mouse primary adipocytes to promote lipolysis (Figure 1) [47]. 
Phosphatidylinositol 3-kinase regulatory subunit 1 (Pik3r1) is another GR primary target 
gene in adipocytes and myotubes [48]. Exogenous glucocorticoid-induced adipose tissue 
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lipolysis is reduced in adipocyte specific Pik3r1 knockout mice [49]. Interestingly, in these 
mice, glucocorticoids still enhance the phosphorylation of Hsl but not perilipin 1 in white 
adipose tissue [49]. Because Hsl is localized in cytosol whereas perilipin 1 is localized on 
lipid droplets before phosphorylation, this data suggests that in Pik3r1 null adipocytes, 
glucocorticoid activated protein kinase A (PKA) is specifically impaired in the lipid droplet. 
Indeed, in white adipose tissue of wild type mice, glucocorticoid treatment increases levels 
of both the catalytic and regulatory subunit of PKA on lipid droplets. But this effect is 
attenuated in adipocyte specific Pik3r1 knockout mice (Figure 1) [49]. Finally, modulating 
the phosphorylation status of GR could affect its ability to regulate lipid metabolism. Protein 
phosphatase 5 (PP5) is a component of hsp90-containing chaperone complex and can 
dephosphorylate GR through its phosphatase activity [50–53]. Mouse embryonic fibroblasts 
(MEF) lacking PP5 showed increased phosphorylation of GR at serine 212 and 234, and 
enhanced dexamethasone effect on lipolytic gene expression [54]. The ability of PP5 
knockout MEFs to differentiate adipocyte is also significantly impaired. This phenotype, 
however, might not be entirely attributed to the regulation of GR activity by PP5, as PP5 also 
regulates PPARγ activity [54].
In contrast to lipolysis, the effect of glucocorticoids on lipogenesis in adipocytes is much 
more complicated. Glucocorticoids decrease lipogenesis in human adipocyte cell line Chub-
S7 [55]. Similarly, in adipocytes differentiated from human primary subcutaneous and 
omen-tal preadipocytes, glucocorticoids also decrease lipogenesis [55]. However, in 
adipocytes also treated with insulin, glucocorticoids either enhance insulin-stimulated 
lipogenesis or, at the very least, do not suppress lipogenesis. [55]. Glucocorticoid treatment 
has been previously shown to increase the expression of certain lipogenic and triglyceride 
synthetic genes, such as fatty acid synthase (Fasn), acetyl-CoA carboxylase 2 (Acacb), 
glycerol-3-phosphate acyltransferase 3 and 4 (Gpat3 and Gpat4) and lipin 1 (Lpin1) in 
adipocytes, and some of these genes are direct target genes of GR [41, 55]. It appears that 
the induction of these genes by glucocorticoids is not able to promote lipogenesis. It is likely 
that other factors, such as insulin, are needed to act with glucocorticoids to enhance 
lipogenesis. Notably, upon insulin resistance, while insulin fails to exert its effects on 
glucose homeostasis, insulin still is able to enhance lipogenesis [56]. Thus, it is conceivable 
that during a state of insulin resistance, glucocorticoids act with insulin to further promote 
lipogenesis.
FoxA3, which encodes a transcription factor, has been identified as a primary target gene of 
GR in adipocytes [57]. Reduction of FoxA3 expression in adipocytes resulted in 
deregulation of more than 60% of glucocorticoid-regulated lipid metabolism genes, such as 
Lipin1, Gpat4, Angptl4, and Lipe [57]. Additionally, they found that in adipocytes, Foxa3 
deficiency suppressed GR-induced lipolysis, but cAMP or PPARα-agonist–induced lipolysis 
was unaffected [57]. Chromatin immunoprecipitation experiments found that reducing 
FoxA3 expression attenuated the recruitment of GR to its genomic response elements [57]. 
In FoxA3 null mice, exogenous glucocorticoid treatment-increased adiposity is 
compromised; however other glucocorticoid-promoted metabolic disorders, such as hepatic 
steatosis, were not affected [57]. The ability of glucocorticoids to induce lipid metabolism 
genes is also attenuated in adipose tissues but not in the liver of FoxA3 null mice [57]. Thus, 
FoxA3 mediates and modulates GR actions specifically in adipocytes.
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4. Regulation of Glucose Metabolism by GR in White Adipocytes
Glucocorticoids have frequently been shown to inhibit insulin-stimulated glucose uptake and 
utilization in adipocytes [25, 58, 59]. One mechanism by which glucocorticoids act to 
suppress insulin stimulated glucose uptake in 3T3-L1 mature adipocytes is to augment the 
production of reactive oxygen species (ROS) [60]. Treating 3T3-L1 adipocytes with anti-
oxidants or overex-pressing genes encoding enzymes that can reduce ROS levels improved 
glucocorticoid-induced insulin resistance [60]. Treating genetically insulin resistant ob/ob 
mice with anti-oxidant, MnTBAP, significantly improved glucose and insulin tolerance [60]. 
Notably, ob/ob mice have elevated plasma corticosterone levels [61]. TNFα (acting through 
NFκB, a heterodimer of p65 and p50) also induces insulin resistance by elevating ROS in 
3T3-L1 adipocytes [60]. Based on these observations, Kang et al. hypothesized that there are 
common “insulin resistance-induced genes” that are regulated by glucocorticoids and TNFα 
independently. Transcriptional profiling was performed and found that 271 dexamethasone-
induced genes whose expression is also stimulated by TNFα treatment [62]. Kang et al. then 
performed chromatin immunoprecipitation sequencing of acetylated histone H3 lysine 27 
(H3K27ac) to identify enhancers that are activated by dexamethasone or TNFα treatment. 
Within 200 kb of these 271 glucocorticoidand TNFα-induced genes, 326 enhancers were 
induced by glucocorticoid treatment whereas 598 enhancers were induced by TNFα 
treatment, but only 53 enhancers were found in both groups [62]. Bioinformatic analysis 
found that in addition to GRE, vitamin D receptor response element is highly presented in 
these 53 enhancers [62]. Indeed, reducing the expression of vitamin D receptor (VDR) in 
3T3-L1 adipocytes reduces the ability of glucocorticoids and TNFα to inhibit insulin–
stimulated glucose uptake [62]. VDR is a potential GR primary target gene, as it contains 
GR binding sites in its genomic region and its expression is induced by glucocorticoids [41, 
62]. Notably, it seems that vitamin D, the ligand of VDR, is not required for the role of VDR 
in glucocorticoid and TNFα induced insulin resistance [62]. Another mechanism that might 
mediate glucocorticoid-induced insulin resistance is the induction of Mkp-1 (a.k.a Dusp1) 
by glucocorticoids [63]. Mkp-1 is a GR primary target gene containing functional GR 
binding sites [64, 65] that encodes a protein phosphatase mainly for p38 MAP kinase. 
Glucocorticoid treatment reduced insulin-induced p38 activation in 3T3-L1 adipocytes [63]. 
Moreover, overexpression of Mkp-1 in 3T3-L1 adipocytes mimicked the inhibitory response 
of glucocorticoids on insulin-stimulated glucose uptake [63]. Inhibition p38 MAP kinase has 
been shown to reduce the maximal induction of insulin-stimulated glucose uptake in 
adipocytes in some reports [66, 67]. However, in some other reports, inhibition of p38 MAP 
kinase does not affect insulin-stimulated glucose uptake in adipocytes [68–70]. The role of 
p38 MAP kinase inhibition in the suppressive effect of Mkp-1 overexpression on insulin-
stimulated glucose uptake was not examined in this report. Furthermore, the role of 
adipocyte Mkp-1 in glucocorticoid effects on insulin sensitivity has not been tested in vivo. 
Thus, the exact role of Mkp-1 in glucocorticoid response in adipocytes requires more 
extensive studies.
Glucocorticoids have also been shown to modulate the expression of several adipokines that 
include plasminogen activator inhibitor-1 (PAI-1, a.k.a Serpine1), lipocalin 2 (Lcn2), and 
Angptl4. PAI-1 is a GR primary target gene [71]. It has been shown that exogenous 
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corticosterone treatment strongly elevated the expression of PAI-1 in circulation and white 
adipose tissues [72]. In both male and female PAI-1 null mice, exogenous corticosterone 
treatment-induced glucose and insulin intolerance were compromised [72]. However, 
glucocorticoid-induced hyperlipidemia was not affected in PAI-1 null mice [72]. Treating 
human HepG2 hepatoma cells with PAI-1 reduced insulin signaling and the suppressive 
effect of insulin on gluconeogenic gene expression. In contrast, PAI-1 did not affect insulin 
signaling in 3T3-L1 adipocytes and C2C12 myotubes. These results suggest that the main 
target tissue for PAI-1-induced insulin resistance is liver [72]. The molecular mechanism 
governing the inhibitory effect of PAI-1 on insulin signaling in hepatocytes, however, is 
largely unclear. Glucocorticoid-induced glucose intolerance and insulin resistance was 
compromised in Angptl4−/− mice [73]. In wild type mice, exogenous glucocorticoid 
treatment stimulated the hepatic ceramide synthetic program, which activated protein kinase 
c ζ (PKCζ) and protein phosphatase 2 A (PP2A) to inhibit insulin action in liver [73]. 
Without Angptl4, however, hepatic ceramide production induced by glucocorticoids was 
significantly attenuated [73]. Therefore, glucose intolerance and insulin resistance were 
improved in exogenous glucocorticoid treated Angptl4−/− mice [73]. Reducing PKCζ and 
PP2A activity both attenuated the ability of glucocorticoids to induce insulin resistance and 
glucose intolerance [73]. Lcn2 is another GR primary target gene [74, 75]. Lcn2 null mice 
were partially protected from high fat diet induced glucose intolerance and insulin resistance 
[76, 77]. However, its role in exogenous glucocorticoid-induced insulin resistance has not 
been tested.
Notably, there are reports showing that while glucocorticoid treatment induces insulin 
resistance in primary adipocytes isolated from human omental white adipose tissue, it 
actually enhances insulin action in human primary subcutaneous adipocytes [26, 27]. The 
molecular basis of this depot specific effect on human primary adipocytes is unknown.
5. TheRole of Adipocyte GR in the Regulation of Metabolic Homeostasis 
in vivo
To analyze the exact role of GR in adipocytes in the regulation of metabolic homeostasis, 
several groups have created adipocyte specific GR knockout mice (AGRKO). The results 
from AGRKO mice are somewhat different between different laboratories (see Table 1). 
Most studies did not find any difference in adiposity in mice fed with chow diet. Most 
studies also did not observe any difference in glucose and insulin tolerance between wild 
type and AGRKO mice when fed with chow diet [45, 46, 78]. However, one report found 
that AGRKO mice are more insulin tolerant [79]. Additionally, they found the activity of 
AKT, a downstream effector of insulin signaling, is higher in the liver of AGRKO mice [79]. 
AGRKO mice had similar Hsl mRNA levels after a 48hr fast, while Atgl and CgI-58 
expression were reduced in AGRKO mice [79], while another group found Plin1 and Hsl 
expression to be reduced in AGRKO mice [45]. They also found that fasting-induced 
adipose tissue lipolysis and hepatic gluconeogenesis are both reduced in AGRKO mice [79]. 
The role of adipocyte GR in adipose tissue lipolysis is supported by two reports. Injecting 
isoproterenol into wild type mice resulted in elevated plasma non-esterified fatty acids 
(NEFA) and glycerol, indicating an increase in adipose tissue lipolysis. This effect is 
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decreased in AGRKO mice [45]. Both basal and isoproterenol-stimulated lipolysis were 
lower in fat explants isolated from AGRKO mice than those of wild type mice [45]. 
Moreover, 48 hour fasting-induced lipolysis was impaired in AGRKO mice [79]. This is 
likely due to the impairment of β-adrenergic receptor signaling in adipose tissue of AGRKO 
mice [79]. PKA activity in epididymal white adipose tissue explants was lower in 48 hour 
fasted AGRKO than wild type mice [79]. Glucocorticoid treatment increased the expression 
of Gsα (a.k.a Gnas) in white adipose tissue but not in liver and skeletal muscle. This 
induction was diminished in AGRKO mice [79]. Notably, adipocyte specific Gsα null mice 
also have defective adipose tissue lipolysis [80]. Whether Gsα is a GR primary target is 
unknown.
Two groups investigated a potential compensatory role of mineralocorticoid receptor (MR) 
[81] in the AGRKO mice. This question is relevant because cortisol/corticosterone 
efficiently bind to and can act through MR. One group found MR mRNA levels in adipose to 
increase slightly, but not significantly [78], while another group found no change in MR 
expression under high fat feeding in AGRKO mice [45]. Additionally, one group examined 
the effects of corticosterone in AGRKO mice [46]. They found that corticosterone treatment 
produced no significant difference in glucose tolerance and insulin sensitivity between wild 
type and AGRKO mice [46]. Notably, comparing to wild type mice, adipocyte specific MR 
knock out mice also showed no significant differences in adipose tissue weight or size, and 
glucose and insulin tolerance under high fat diet feeding [82]. Interestingly, overexpressing 
MR specifically in adipocytes has been shown to increase body weight, fat mass, and insulin 
resistance in mice [83]. Thus, while adipocyte MR might play a minor role in 
glucocorticoid- and high fat diet-induced metabolic disorders, increasing MR activity in 
adipocytes causes negative impacts on metabolic homeostasis. Previous reports have shown 
that treating high fat diet fed mice with MR antagonists induced the beiging of both visceral 
and inguinal white adipose tissue and improved glucose tolerance and adipose tissue 
dysfunction by reducing reactive oxygen species production and inflammatory process [84, 
85]. Based on adipocyte specific MR knockout studies, the phenotypes observed in these 
reports could be due to the effects of MR antagonists on tissues other than adipose tissues.
Two groups looked at hypothalamus-pituitary-adrenal (HPA) axis function in AGRKO mice. 
In one study, compared to wild type mice, acute 30 minute restraint, a psychogenic stressor, 
causes hypersecretion of corticosterone and hyperglycemia in AGRKO mice [86]. Injecting 
low dose dexamethasone for 2 hours prior to the restrain t showed that AGRKO mice are 
able to escape from dexamethasone suppression faster than wild type mice [86]. Another 
study performed a dexamethasone suppression test, looking at corticosterone levels before 
and 4 hours after a 1mg/kg dose of dexamethasone. This study found equal suppression of 
corticosterone in AGRKO vs. wild type mice [46]. A possible reason for the discrepant data 
is an influence of adipose GR on the stress response vs. direct pharmacologic treatment. It is 
not clear how adipose GR would influence the HPA axis. Another possible explanation 
could be a developmental compensation arising during development. Finally, it is also 
possible that there exists a circuit between adipose sensory nerves and the hypothalamus.
Under high fat diet feeding, three reports did not observe significant differences in adiposity, 
as well as glucose and insulin tolerance between wild type and AGRKO mice [45, 46, 78]. 
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However, the other two reports found that AGRKO mice gain weight slower than wild type 
mice [79, 86]. Moreover, glucose tolerance was found to be improved in AGRKO mice [79]. 
Plasma insulin levels were lower and insulin-induced AKT activity were improved in 
AGRKO mice [79]. High fat diet-induced hepatic steatosis and lipogenic gene expression 
were also reduced in AGRKO mice [79]. In addition to high fat diet feeding, aging-induced 
body weight gain and hepatic steatosis were also compromised in AGRKO mice in this 
report [79]. High fat diet induced inflammation in epididymal white adipose tissue was 
enhanced in AGRKO mice [78]. These results are in agreement with the anti-inflammatory 
functions of GR and previous observations show how glucocorticoid treatment, despite 
causing insulin resistance, attenuates high fat diet induced macrophage recruitment into 
white adipose tissue [87].
The response of AGRKO mice to exogenous glucocorticoid-induced insulin resistance also 
differed between different studies. In one study, exogenous glucocorticoid-induced glucose 
and insulin intolerance were improved in AGRKO mice [45]. Glucocorticoids inhibit 
insulin-stimulated Akt activity in the soleus muscle of wild type mice, which was also 
compromised in AGRKO mice [45]. In another study, wild type and AGRKO mice were 
treated with either synthetic glucocorticoid dexamethasone or physiological glucocorticoid 
corticosterone. However, no significant difference in adiposity, glucose and insulin tolerance 
were observed between wild type and AGRKO mice [46]. One difference between these two 
studies is that one study treated mice with dexamethasone for 2 months (2mg/kg body 
weight/day) [45], whereas the other study treated mice with dexamethasone for 2 weeks 
(10mg/kg body weight/day) or corticosterone (10mg/kg body weight/day) for 4 weeks [46]. 
Whether the difference in duration and dose of ligand treatment can result in distinct 
outcomes is unclear.
Notably, among these 5 studies, 32 of them used the same GR-flox mice generated by the 
Schütz lab [88] (Table 1). In contrast, 2 used GR-flox mice generated from the Ashwell lab 
[89] and de Kloet et al. used GR-flox mice generated from the Muglia lab [90] (Table 1). 
Nonetheless, sometimes, different laboratories observe distinct metabolic outcomes even for 
the same transgenic or knockout mouse lines. Multiple studies on AGRKO mice, thus, are 
valuable. We do not know the exact reasons for the differential observations between these 
studies. However, the overall results demonstrate that adipocyte GR plays a role in whole 
body metabolic homeostasis in vivo. This role may appear less obvious in AGRKO mice if 
developmental compensation occurs. The robust difference in the serum metabolome 
described in one study is potential evidence for such compensation [91].
6. The Role of GR in the Regulation of Brown and Beige Adipocyte 
Function
It has been shown that glucocorticoid treatment in rodents decreases thermogenic activity of 
BAT and suppresses beiging. In rodents, glucocorticoids have been shown to reduce the 
expression of uncoupling protein 1 (Ucp1) [29, 92], which encodes a protein that is 
specifically expressed in brown and beige adipocytes required to generate heat during 
adaptive thermogenesis [93, 94]. Moreover, adrenalectomy and GR antagonist increased the 
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expression of Ucp1 and elevates BAT thermogenesis [28, 95, 96]. Similarly, mice lacking 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1−/−) were protected by suppression of 
BAT activity by exogenous glucocorticoids [97]. Although the expression of Ucp1 was 
similar between corticosterone treated wild type and 11β-HSD1−/− mice, several genes 
encoding proteins in the activation of thermogenesis and mitochondrial respiration were 
expressed in lower levels in 11β-HSD1−/− mice [97]. Treating primary brown adipocytes 
isolated from wild type mice with corticosterone reduced oxygen consumption and the 
expression of thermogenic genes, such as Ucp1, and brown/beige makers Cox8b and 
Cox7a1, which encodes proteins involved in mitochondrial oxidative phosphorylation [97]. 
Interestingly, although corticosterone still suppressed the expression of thermogenic and 
mitochondrial genes in primary brown adipocytes isolated from 11β-HSD1−/− mice, the 
basal expression of these genes was higher than those of wild type mice [97]. Similarly, the 
oxygen consumption rate was also higher in primary brown adipocytes of 11β-HSD1−/− 
mice [97]. These results suggest that the glucocorticoid effect on thermogenesis is cell 
autonomous. Notably, lysine-specific demethylase 1 (Lsd1) promotes BAT thermogenesis by 
inhibiting 11β-HSD1 expression in BAT [98]. Adipocyte specific Lsd1 deletion impaired 
mitochondrial fatty acid oxidation capacity of BAT, reduced whole-body energy expenditure, 
and increased fat deposition [98]. These phenotypes, however, were alleviated by deleting 
11β-HSD1 concurrently [98]. Overall, glucocorticoids appear to have species-specific 
effects on BAT activation. In humans, glucocorticoid treatment has been shown to increase 
BAT activity and UCP-1 expression [32, 99]. However, chronic glucocorticoid treatment in 
human adipocytes did decrease UCP-1 expression after 48hrs of treatment [32].
AGRKO mice are generated by crossing GRflox/flox mice with mice expressing Cre recom 
binase driven by an adiponectin promoter. Since adiponectin is expressed in both white and 
brown adipose tissue, GR is also deleted in the brown adipocytes of these mice. When wild 
type and AGRKO mice were fasted for 4 hours, and then placed in 4°C for 4 hours, the body 
temperature of AGRKO was significantly lower than that of wild type mice [79]. The 
histology of brown adipose tissue, however, showed that the lipid droplet size is smaller in 
the BAT of AGRKO than that of wild type mice [79]. Based on these observations, it was 
suggested that lipolytic activity was not affected by GR deletion in BAT upon cold exposure. 
The lipogenic activity of BAT in AGRKO mice upon cold exposure was not evaluated. Cold-
induced plasma NEFA and ketone bodies levels were lower in AGRKO mice, for which the 
authors suggested that these phenotypes were due to the decreased lipolysis in WAT [79]. 
Another study found that glucocorticoid treatment increased the lipid accumulation in BAT 
of wild type but not AGRKO mice [45]. In agreement with this observation, another report 
found that glucocorticoid treatment elevated the expression of lipogenic genes in BAT of 
wild type mice. This effect was attenuated in AGRKO mice [46]. Notably, glucocorticoid 
treatment did not affect the expression of Ucp1 and mitochondrial genes in BAT of wild type 
and AGRKO mice [45]. In BAT of wild type mice, glucocorticoid treatment enhanced 
whitening genes, such as resistin and leptin, which are usually highly expressed in white but 
not brown adipocytes. This effect is diminished in AGRKO mice [45]. Overall, GR regulates 
lipogenic and whitening genes instead of thermogenic genes in brown adipocytes to 
modulate brown adipocyte functions.
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Glucocorticoids have also been shown to reduce the browning of white adipose tissue. Cold 
exposure activates the HPA axis, which increases the circulating adrenocorticotropic 
hormone (ACTH) and corticosterone in mice [95]. In primary adipocytes isolated from 
inguinal white adipose tissue, ACTH promoted the expression of Ucp1, which is attenuated 
by corticosterone treatment [95]. Glucocorticoids activated the transcription of miRNA, 
miR-27b, which targets Prdm16 [30], which encodes a transcriptional coregulator that plays 
a key role in the differentiation of beige adipocytes. The reduction of Prdm16 expression in 
turn decreased the expression of Ucp1. Injecting lentivirus expressing antisense against 
miR-27b through tail vein effectively reduced the expression miR-27b in both subcutaneous 
and visceral adipose tissue [30]. This increased whole body energy expenditure and reduced 
adiposity in glucocorticoid-treated animals [30]. Glucocorticoids also activated another 
miRNA, miR-19b, which targets β1 adrenergic receptor (Adrb1), in primary adipocytes of 
subcutaneous white adipose tissues [31]. Overexpression of miR-19b reduced the expression 
of Ucp1 and oxygen consumption in adipocytes differentiated from precursor cells isolated 
from subcutaneous adipose tissues [31]. In contrast, reducing expression of miR-19b 
enhanced Ucp1 expression and oxygen consumption in these primary subcutaneous 
adipocytes [31]. Reducing miR-19b expression also blocked the ability of glucocorticoids to 
suppress Ucp1 expression and oxygen consumption[31]. Finally, while cold exposure 
induces beiging of subcutaneous white adipose tissues, warming (such as thermoneutrality, 
30°C) “whitens” beige and brown adipose tissues [100, 101]. A recent study found that GR 
plays a critical role in the induction of whitening gene expression. Thus, compared to wild 
type mice when AGRKO mice were moved from 1 week 4°C treatment to 30°C for another 
week, the induction of whitening genes was delayed [102]. In contrast, mice put under cold 
exposure for 1 week and then injected with dexamethasone for another week while 
remaining at 4°C, displayed elevated expression of whitening genes but thermogenic gene 
expression was reduced [102].
Interestingly, injecting a synthetic glucocorticoid, prednisolone, into healthy humans during 
mild cold exposure (16–17°C) showed increased glucose uptake in BAT [32]. Moreover, in 
lean subjects, prednisolone treatment also increased supraclavicular skin temperature and 
energy expenditure in cold but not warm conditions [32]. These acute glucocorticoid 
responses were not observed in rodents. Glucocorticoid treatment increased isoprenaline-
stimulated respiration and UCP1 expression in human primary brown adipocytes [32]. These 
results are also opposite to those found in murine primary brown and beige adipocytes. 
Thus, glucocorticoids exert species-specific effects on brown adipocyte functions. Another 
study found that including dexamethasone in the differentiation media of human primary 
brown adipocytes enhanced basal UCP1 expression and oxygen consumption rate [99]. 
However, isoprenaline-stimulated UCP1 expression and oxygen consumption rate were 
reduced by dexamethasone treatment [99]. In this study, 1 or 10 μM dexamethasone was 
used [99], whereas another study treated human primary brown adipocytes with cortisol for 
up to 1 μM [32]. Notably, dexamethasone is approximately 10 times more potent than 
cortisol. It is unclear whether the difference in ligands and doses used in the experiments 
resulted in these distinct observations.
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7. Conclusion
Recent studies have made significant progress in establishing the role of adipocyte GR in 
whole body metabolic homeostasis. Nonetheless, many glucocorticoids and GR functions in 
adipocytes remain to be elucidated. For example, how do glucocorticoids and GR 
specifically promote central obesity in humans? What is the molecular basis of species-
specific effects of glucocorticoids on brown adipocytes? One consistent observation in 
AGRKO mice is the role of adipocyte GR in the regulation of adipocyte lipolysis. Despite 
the identification of GR primary target genes involved in this process, the comprehensive 
understanding of this glucocorticoid regulated process, especially in vivo, requires more 
study. Moreover, does adipocyte GR play a role in specific physiological states that require 
the elevation of adipocyte lipolysis, such as exercise? Overall, with the availability of 
AGRKO mice and new methodology, such as CRISPR, we expect to learn more about 
glucocorticoids and GR function in adipocytes in the near future.
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Figure 1: The mechanism of glucocorticoid-induced lipolysis in adipocytes.
Glucocorticoids activate several mechanisms to promote lipolysis in adipocytes. First, 
glucocorticoids decrease the expression of Pde3b, which results in the activation of cAMP 
signaling. Second, a list of lipolytic genes, Atgl, Hsl, and Mgll, are transcriptionally 
activated by GR. Angptl4 is another GR target gene, which encodes a secreted protein that 
binds to an unidentified receptor to stimulate cAMP production to activate lipolysis. Pik3r1 
is an additional GR primary target gene that encodes a protein required for increasing PKA 
levels in the lipid droplet upon glucocorticoid treatment. Phosphorylation of Plin1 by PKA 
in the lipid droplet allows CGI-58 to dissociate from Plin1 and serves as an Atgl coactivator 
to promote lipolysis.
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Table 1:
Comparison of Adipocyte GR Knock Out Mouse Studies.
Mouse Design Shen et al [45] Adipoq-Cre FVB/NJ background (Jackson Laboratory, 010803), GR floxed exon 3 [89] (Jackson 
Laboratory, B6.Cg-Nr3cItml.lJda/J, 021021)
Bose et al [46] Adipoq-Cre FVB/NJ background (Jackson Laboratory, 010803), GR floxed exon3 [89]
Desarzens et al [78] Adipoq-Cre FVB/NJ background (Jackson Laboratory, 010803), GR floxed exon 3 [88]
Mueller et al [91] Adipoq-Cre FVB/NJ background (Jackson Laboratory, 010803), GR floxed exon 3 [88]
de Kloet et al [86] Adipoq-Cre C57BL/6 × 129 background. GR floxed exon 2 [90]
Fasting Shen et al [45] No change in fasting plasma insulin levels in both Chow and HFD. 4 hr fast showed no difference in 
plasma NEFA and glycerol but reduced lipolysis under isoproterenol stimulation
Bose et al [46]
Desarzens et al [78]
Mueller et al [91] AGRKO mice after 48hr fast. 2× higher body fat mass than controls. Increased fasting blood glucose. 
Impaired upregulation of fasting induced gene expression. AGRKO mice eWAT had decreased 
phosphorylation of HSL and perilipin. AGRKO had reduced cAMP generation, NEFA release.
de Kloet et al [86]
Chow Shen et al [45] No difference in body weight or composition. No difference in glucose tolerance or insulin sensitivity
Bose et al [46] No difference in bodyweight and fat mas
Desarzens et al [78] No difference in bodyweight, fat mass, or adipocyte size. No difference in plasma free fatty acids, and 
cholesterol. Slight decrease in TG levels in AGRKO mice. No difference in glucose and insulin levels
Mueller et al [91] 4hr and 16 hr fasting blood glucose and plasma insulin levels showed no difference. No difference in 
GTT, but ITT showed delayed posthypoglycemic recovery likely due to decreased hepatic glucose 
production. Increased insulin induced AKT phosphorylation. Lower liver TG levels. Reduced NEFA 
release from 4hr and 16hr fasted AGRKO eWAT. Lower blood glucose levels during PTT in AGRKO 
mice
de Kloet et al [86] No difference in body weight, body mass, adiposity, and adipocyte morphology. NO difference in 
basal glucose levels. Unchanged adiponectin, insulin, and leptin in AGRKO mice
HFD Shen et al [45] 14 week 58% Fat diet*: AGRKO trending to gain more weight. KO has decreased plasma TG and 
NEFA. Small increase in Gpat4 in eWAT. In liver, trending to decreased lipid metabolism and 
gluconeogenic genes with Mttp being significant. GTT and ITT no difference
Bose et al [46] 16 weeks 42% Fat diet*: Similar body composition, BMD, BMC. No difference in glucose levels, 
GTT, nor ITT No difference in liver TG levels.
Desarzens et al [78] 15 weeks 21.2% fat, 34.5% sucrose diet*: No difference in bodyweight, fat mass, or adipocyte size. 
No difference in plasma free fatty acids, triglycerides, and cholesterol. No difference in glucose and 
insulin levels. AGRKO mice on HFSD had increased area under the curve for GTT compared to fl/fl, 
which remained the same. Histology of adipose showed more crown-like structures in AGRKO mice, 
increased lipolcalin-2 and increased activation of JNK without effects on ERK1/2
Mueller et al [91] 20 weeks 34.6% Fat diet* Reduced HFD induced obesity, decreased weight gain, reduced hepatic 
steatosis, improved glucose tolerance. Decreased FA and NEFA. Decreased expression of FA storage 
genes (Acaca, Gpat2, Dgat2, Pck1, Slc27a1 in eWAT. AGRKO mice had lower WAT weights than 
controls, No difference in plasma corticosterone levels, AGRKO mice had improved glucose 
tolerance and increased insulin sensitivity. AGRKO had decreased hepatic steatosis and decreased 
expression of Fasn, Gpat1, Pparq, Cd36, and Slc27a4 in liver.
de Kloet et al [86] 40% fat diet*: AGRKO mice gain significantly less weight. Decreased adipose mass, decreased 
energy consumption.
Exogenous GC Shen et al [45] 3mg/kg** Dexamethasone IP every other day for 2 months. No difference in body weight. Trend 
towards increased eWAT and iWAT. AGRKO mice more glucose and insulin tolerant than Flox mice. 
Improved insulin sensitivity in muscle. Decreased ability of Dex to induce whitening of BAT and 
Stimulated lipolysis.
Bose et al [46] 10mg/kg** Dexamethasone for 2 weeks. No difference in blood glucose levels at baseline, GTT, or 
ITT. No difference in body composition, but AGRKO mice had higher fat mass than WT 10mg/kg 
Corticosterone 4 weeks: No difference in baseline blood glucose nor GTT and ITT. No difference in 
bodyweight, fat mass, BMD, nor liver TG levels
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Desarzens et al [78]
Mueller et al [91]
de Kloet et al [86] 0.1mg/kg** Dexamethasone injected AGRKO mice showed under stress an impaired negative 
feedback of HPA
BAT Shen et al [45] Cold exposure showed lower glycerol and NEFA levels in AGRKO mice.
Bose et al [46] 10mg/kg acute Dexamethasone for 6 hrs resulted in upgregulation of some, but not all metabolism 
genes in AGRKO mice BAT.
Desarzens et al [78]
Mueller et al [91] 4hr fast followed by 4h 4°C. Ability to maintain body temperature at 4°C was reduced. Lipid droplet 
decreased more in AGRKO BAT. Decreased cold induced thermogenesis due to impaired lipolysis 
and NEFA flux.
de Kloet et al [86]
HPA Axis Shen et al [45]
Bose et al [46] Dexamethasone suppression test showed decrease in AGRKO mice after Dexamethasone injection 
showing HPA axis activation was not altered.
Desarzens et al [78]
Mueller et al [91]
de Kloet et al [86] Similar baseline corticosterone levels. Under stress, AGRKO mice had increased corticosterone and 
hyperglycemia
Note:
*
High fat diet use in the papers ranged from 21%–58% fat.
**
Dexamethasone doses ranged from 0.1mg/kg to 3mg/kg and varied in duration from acute to chronic exposure. These high fat diet percentages as 
well as doses of dexamethasone could be responsible for the differences observed by the papers.
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